“Recent changes in legislation are allowing Japanese pharmaceutical companies to extend clinical trials normally conducted in Japan to other countries in Asia, but these companies have had difficulty finding central lab services that are harmonised throughout the region,” said Tom Wollman, senior vice-president, Quintiles Global Central Laboratories. “With CAP-certified labs in Beijing, Singapore, Mumbai and now Japan, we can provide well-controlled processes and harmonised testing services throughout the Asia-Pacific region … This lab, along with all labs in our network, will follow the same standard operating procedures, and data will be available on our QNET database.”
Medca provides a range of laboratory services, including biochemical, endocrine, tumour marker, drug-level, immunology and microbiological testing. The laboratory has undertaken specimens for examination from about 4,000 medical institutions throughout Japan. “This collaboration with Quintiles will be very helpful for the future success of Medca Japan,” said president Yutaka Kannari. “We receive more than 30,000 specimens for examination per day, and this relationship will allow us to strengthen our clinical trial services while supporting continued growth of our existing laboratory operations.”
The relationship with Medca will be managed within Quintiles by Alan Ong, vice-president and general manager, Quintiles Labs Asia, who will give technical guidance, and Yoh Narimatsu, president, Quintiles Transnational Japan, who will provide expertise on the Japanese market. Article submitted by www.jobs4dd.com, a specialist online recruitment service for the clinical trial and drug development sectors.
